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ROCa b s t r a c t
Chromosomal microarrays (CMAs) are routinely used in both research and clinical laboratories; yet, little
attention has been given to the estimation of genome-wide true and false negatives during the assess-
ment of these assays and how such information could be used to calibrate various algorithmic metrics
to improve performance. Low-throughput, locus-speciﬁc methods such as ﬂuorescence in situ hybridiza-
tion (FISH), quantitative PCR (qPCR), or multiplex ligation-dependent probe ampliﬁcation (MLPA) pre-
clude rigorous calibration of various metrics used by copy number variant (CNV) detection algorithms.
To aid this task, we have established a comparative methodology, CNV-ROC, which is capable of perform-
ing a high throughput, low cost, analysis of CMAs that takes into consideration genome-wide true and
false negatives. CNV-ROC uses a higher resolution microarray to conﬁrm calls from a lower resolution
microarray and provides for a true measure of genome-wide performance metrics at the resolution
offered by microarray testing. CNV-ROC also provides for a very precise comparison of CNV calls between
two microarray platforms without the need to establish an arbitrary degree of overlap. Comparison of
CNVs across microarrays is done on a per-probe basis and receiver operator characteristic (ROC) analysis
is used to calibrate algorithmic metrics, such as log2 ratio threshold, to enhance CNV calling performance.
CNV-ROC addresses a critical and consistently overlooked aspect of analytical assessments of genome-
wide techniques like CMAs which is the measurement and use of genome-wide true and false negative
data for the calculation of performance metrics and comparison of CNV proﬁles between different
microarray experiments.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Chromosomal microarray (CMA) is a broad term used to
describe testing for copy number variation utilizing either single
nucleotide polymorphism (SNP) or comparative genomic
hybridization (CGH) microarrays. CMA has been used in research
for years and has also proven valuable in the clinical setting
exhibiting a much higher diagnostic yield than conventional chro-mosome analysis and/or subtelomeric ﬂuorescence in situ
hybridization (FISH) for a range of developmental phenotypes
[1–3]. The American College of Medical Genetics and Genomics
(ACMG) recommends that CMA be used as a ﬁrst tier diagnostic
test in the evaluation of patients with multiple congenital anoma-
lies not speciﬁc to a well-delineated genetic syndrome, non-syn-
dromic developmental delay/intellectual disability, and autism
spectrum disorders [2,4]. The ACMG has also published guidelines
for the interpretation and reporting of constitutional copy number
variants (CNVs) as well as for the design and performance expecta-
tions of microarrays used in clinical CMA testing [5]. The ACMG
recommends that CMA platforms should be able to detect gen-
ome-wide CNVs of at least 400 Kb at 99% analytical sensitivity
(with a lower limit at the 95% conﬁdence interval >98%) and a
false-positive rate of <1% [5]. In order to generate such perfor-
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false positives but also regions called diploid by a CMA must also
be classiﬁed at either true or false negatives.
Evaluation of a CMA platform typically involves the selection of
several dozen or more well-characterized cases that contain a col-
lection of appropriately sized (majority being <1 Mb), unique CNVs
that are located throughout the genome. For smaller laboratories,
or those just starting up the assay, the collection of enough appro-
priate cases can be difﬁcult. We sought to develop a method that
could aid the CMA evaluation process by allowing laboratories to
calculate performance metrics in a high-throughput, low cost
way that relied on fewer cases. This method can utilize both
unique and common/polymorphic CNVs and is based on a per-
probe approach to quantify outcome metrics such as true and false
positive and negative results, as well as sensitivity/recall, speciﬁci-
ty, and precision. Calculation of precision is critical given the dis-
proportionate amount of true negative data in such genome-wide
comparisons (most of the genome will not be affected by a CNV).
Using two CMA designs that differ in the level of resolution we
show that performance metrics can be adequately calculated with
as few as 20 cases. This approach relies on comparing the CNV pro-
ﬁles of the same samples run on different CMA designs, however,
by using a per-probe approach, an arbitrary decision concerning
the minimal degree of overlap two CNVs must share in order to
be called the ‘‘same’’ CNV is not necessary and thus provides for
a much more granular analysis of copy number data. In addition,
the high-throughput nature of this comparative methodology
allows for the simultaneous calibration of algorithm metrics such
as log2 ratio threshold, minimum number of probes to call a
CNV, or others. We created several Perl scripts, CNV-ROC, that
can be executed to accomplish this methodology.
In the clinical setting, CMA testing inﬂuences management of
patients in many ways including generation of medical referrals,
and providing guidance for diagnostic imaging and speciﬁc labora-
tory testing [6]. Given the complexity of CMA testing and the
implications it holds for future patient management, the ability
to assess quality control and performance metrics in a variety of
ways can be very useful. Even if manufacturers of chromosomal
microarrays have performed extensive validation, it is still neces-
sary for individual laboratories to establish for themselves the per-
formance characteristics in their own setting and with their unique
set of samples. Thus, the establishment of a comprehensive and
low cost method of measuring the performance of a given CMA
platform is of great signiﬁcance to the laboratory community.2. Methods
2.1. Microarray protocols
In order to test this quality control method, genomic DNA was
isolated from residual clinical peripheral blood samples using the
Puregene Blood Kit (Qiagen; Valencia, CA). DNA quantiﬁcation
and quality assessment was performed using a NanoDrop spec-
trophotometer (Thermo Scientiﬁc; Wilmington, DE) and agarose
gel electrophoresis. For NimbleGen array-CGH experiments, label-
ing of the patient sample and the normal male or female reference
(Promega; Madison, WI) was performed by primer extension of
Cy3 and Cy5 labeled random nonamers (TriLink Biotechnologies;
San Diego, CA), respectively. The labeled patient and reference
DNA were quantitated and equal amounts were hybridized to a
human CGH 385 K Whole-Genome Tiling version 2.0 array or a
human CGH 720 K Whole-Genome Tiling version 3.0 array (Roche
NimbleGen; Madison, WI) according to the manufacturer’s instruc-
tions. Median probe spacing on the 385 K and 720 K arrays is
approximately 7 Kb and 2.5 Kb, respectively. Post-hybridizationprocedures were performed according to the manufacturer’s
instructions. The NimbleScan software tool (version 2.5; Roche
NimbleGen) was used for feature extraction, calculation of log2
ratio values, and calculation of several quality control metrics.
CNV calling and data interpretation were performed using the
Nexus Copy Number software tool (version 6.1, BioDiscovery; El
Segundo, CA) and FASST2 algorithm supplied with the Nexus soft-
ware suite (Supplemental Materials) [7]. Whereas in this study we
chose to use the FASST2 algorithm for CNV detection any algorithm
can be used with CNV-ROC. For the comparison with the Affyme-
trix CytoScan HD array the data from the 720 K NimbleGen array
was converted from hg18 coordinates to hg19 coordinates.
For the Affymetrix CytoScan HD microarray experiments, pro-
cessing of the patient sample was performed by end point PCR
ampliﬁcation using DNA taq polymerase (Clontech, Inc.; Mountain
View, CA). The labeled patient DNA was hybridized to a human
whole genome array containing 1.9 million non-polymorphic
markers, as well as 750,000 SNP probes (Affymetrix; Santa Clara,
CA), according to the manufacturer’s instructions. Median probe
spacing is approximately 1 Kb. Post-hybridization procedures were
performed according to the manufacturer’s instructions. The ChAS
(Chromosome Analysis Software) tool (version 1.1.2; Affymetrix)
was used for feature extraction, calculation of log2 ratio values,
and calculation of several quality control metrics (Supplemental
Materials). CNV calling and data interpretation were performed
with the .CEL ﬁles using the Nexus Copy Number software tool
and SNP-FASST2 algorithm supplied with the Nexus software suite
(Supplemental Materials).
Samples undergoing testing had to meet several quality control
thresholds for inclusion (Supplemental Materials). Several differ-
ent log2 ratio thresholds were utilized for CNV detection, however
10 probes was the consistent minimum CNV size used for all array
types. Based on this minimum number of probes, we conservative-
ly estimated the approximate minimal size CNV detectable by each
array type to be 100 Kb for the 385 K array, 50 Kb for the 720 K
array, and 20 Kb for the CytoScan HD array. All experiments and
analyses performed were replicated in a comparison of the 385 K
array to the NimbleGen human CGH 2.1 M Whole-Genome Tiling
version 2.0 array (Supplemental Materials).2.2. Comparison samples and calculations
Forty samples were used for comparisons, 20 unique samples
for the 385 K vs. 720 K microarray comparisons and 20 additional
samples for the 720 K vs. CytoScan HD microarray comparisons.
All cases were previously analyzed and interpreted by standard
clinical criteria. The distribution included both normal (no known
pathogenic CNVs) and abnormal cases in which a known patho-
genic lesion was identiﬁed (i.e. 17q12 or 22q11.2 deletion). An
appropriate mix of male and female patients, as well as small
(100–400 Kb) and large (>400 Kb) duplications and deletions were
present. The CNVs present in these cases covered a signiﬁcant por-
tion of the genome (Supplemental Tables 3 and 4). Additionally,
each case contained between 10 and 40 common, polymorphic
CNVs. Sensitivity, speciﬁcity, false positive rate, recall and preci-
sion were calculated using conventional methods. Sensitivity
(which is identical to recall) was calculated as the ratio of true
positives to the sum of the true positives and false negatives, speci-
ﬁcity was calculated as the ratio of true negatives to the sum of the
true negatives and false positives. The false positive rate was calcu-
lated as the ratio of false positives to the sum of the false positives
and true negatives, and precision was calculated as the ratio of true
positives to the sum of the true positives and false positives. The
95% conﬁdence intervals were calculated according to the efﬁ-
cient-score method [8].
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For this study, CNVs were divided into two groups: common,
clinically benign CNVs and unique, clinically signiﬁcant CNVs.
Common CNVs were deﬁned as annotated segmental duplications.
A list of these features was obtained using the ‘‘Table Browser’’ fea-
ture of the UCSC Genome Bioinformatics site (http://genome.ucsc.
edu/index.html). Many of these locations also overlapped with
CNVs detected in HapMap samples as ascertained by Conrad and
colleagues [9] using a 42 million feature NimbleGen array
platform.3. Results
3.1. Manual CNV-based comparison
To illustrate the advantages of computer-aided evaluation, we
ﬁrst performed a manual comparison between two NimbleGen
array-CGH platforms of different resolution by visually examining
each CNV called by Nexus Copy Number (version 6.1; FASST2 algo-
rithm) on each array type for each case. For this assessment, only
one log2 ratio threshold (0.3) was used for all cases on both array
types (+0.3 for duplications and 0.3 for deletions). When we refer
to a log2 ratio threshold it is implied that it is negative for deletions
and positive for duplications. Special attention was given to iden-
tify whether or not any CNV detected by the higher resolution
array type would have been expected to be detected on the lower
resolution array type. Using the 720 K array as the surrogate ‘‘gold
standard’’ for the 385 K array, CNVs of appropriate size (>100 Kb on
each array type) were compared to one another to assess true and
false positives and negatives on the 385 K array with respect to the
720 K array. True positives were deﬁned as CNVs >100 Kb on
the 385 K array that had a corresponding CNV present on the
720 K array; false positives were deﬁned as CNVs >100 Kb on
the 385 K array without any corresponding CNV of any size on
the 720 K array; and false negatives were deﬁned as CNVs
>100 Kb on the 720 K array without any corresponding CNV on
the 385 K array. True negatives were deﬁned as those intervening
regions between CNVs of >100 Kb on the 720 K array that had no
corresponding CNV regions on the 385 K array. Analyses were per-
formed using a CNV size threshold of 400 Kb and 100 Kb, as well as
for both benign CNVs and clinically signiﬁcant CNVs, and for
clinically signiﬁcant CNVs only (Supplemental Table 1). Based on
the results of this per-CNV manual comparison of twenty cases
and a size threshold of 400 Kb for all CNVs, a sensitivity of 80.9%
(with a lower limit at the 95% conﬁdence interval of 66.3%) and
speciﬁcity of 99.2% (false positive rate of 0.8% with a higher limit
at the 95% conﬁdence interval of 2.2%) was achievable. However,
when examining only those CNVs >400 Kb and clinically signiﬁcant
(known pathogenic lesions and novel CNVs of unclear clinical sig-
niﬁcance) a sensitivity of 100% and a speciﬁcity of 100% (false posi-
tive rate of 0%) were achieved. When testing the lower size
threshold of 100 Kb, a sensitivity of 79.8% (with a lower limit at
the 95% conﬁdence interval of 74.4%) was achievable when using
data from all CNVs (benign and clinically signiﬁcant) greater than
100 Kb and a single log2 ratio threshold of 0.3. When examining
CNVs >100 Kb and only those that were likely to be clinically sig-
niﬁcant we achieved the same 100% sensitivity and speciﬁcity as
with the 400 Kb analysis.
Aside from the laborious nature of this type of manual analysis
it is also clear that with a per-CNV based analysis and these few
cases there are not enough CNVs to truly establish precise and
meaningful sensitivity and speciﬁcity measures. When examining
only clinically signiﬁcant CNVs greater than 400 Kb a mere 18
CNVs were available for analysis. Even though the sensitivity andspeciﬁcity were each 100%, the 95% conﬁdence intervals were quite
large (sensitivity with a lower limit at the 95% conﬁdence interval
of 78.1% and speciﬁcity with a lower limit at the 95% conﬁdence
interval of 99.0%). Additionally, when visually examining these
CNVs it was easier to determine when two CNVs were the same
despite changes in breakpoints or fragmented calls. Lastly, because
of the extensive time and effort involved in performing this manual
comparison only one log2 ratio threshold could be examined for
each array type precluding any analysis that might identify a dif-
ferent log2 ratio threshold that would further increase sensitivity
without a signiﬁcant loss in speciﬁcity via receiver operator char-
acteristic (ROC) analysis.
Our goal was to create a computer-aided approach to overcome
the limitations described above so that laboratories could assess
the performance characteristics of a whole-genome microarray to
detect CNVs using two microarray platform designs that differed
primarily in their level of resolution. To demonstrate the utility
of this approach we used two different NimbleGen CGHmicroarray
designs and designed several command line executable Perl scripts
collectively called CNV-ROC. Both microarray designs were whole
genome, unbiased CGH microarrays (not targeted arrays). To show
that the method is robust we also repeated the analysis comparing
one of the NimbleGen CGH microarrays to an array manufactured
by Affymetrix (CytoScan HD) that contains both copy number and
single nucleotide polymorphism probes. An additional assessment
comparing yet another type of NimbleGen CGH microarray was
also performed and the results were very similar (Supplemental
Fig. 1).
3.2. Analysis of array metrics
Even though CNV-ROC can be used to calibrate any algorithmic
metric, in lieu of an exhaustive effort we sought to determine
which array metric would be most appropriate to calibrate during
ROC analysis. We did this by creating a separate command line uti-
lity using Perl to computationally compare CNV calls produced by
Nexus Copy Number using the FASST2 algorithm between two dif-
ferent arrays (Supplemental Materials). Whereas our method of
calling CNVs was using the FASST2 algorithm any CNV calling algo-
rithm would work with our methodology. The 720 K array was
again treated as a ‘‘gold standard’’ to which the 385 K array data
was then compared. A previously ﬂuorescence in situ hybridization
(FISH)-validated log2 ratio threshold value of 0.3 was used for the
FASST2 algorithm when calling the CNVs for both array platforms.
The analysis was performed for CNV calls of 400 Kb or greater and
of 100 Kb or greater. In the 385 K CNV set, for 20 samples there
were a total of 45 CNVs that were greater than 400 Kb and a total
of 283 CNVs greater than 100 Kb (Table 1). For each experiment,
every CNV in the 385 K array was checked for any overlapping
CNV calls from 720 K array. From this, two sets of CNVs could be
created for each size-cutoff experiment, one set that had one or
more overlapping 720 K CNVs (true positives) and one set that
had no overlapping 720 K CNVs (false positives). From each set,
the median and mean values were calculated for the: CNV probes’
log2 ratio, CNV size in base pairs, and number of probes in the CNV.
In the 100 Kb CNV size cutoff analysis, CNVs with overlapping
720 K CNVs had a higher mean log2 ratio value (0.542 vs 0.506)
and a higher median log2 value (0.477 vs 0.452) than the 385 K
CNVs with no overlapping 720 K CNVs (ie true positive CNVs had
a higher mean and median log2 ratio value than false positive
CNVs). In the 400 Kb CNV size cutoff analysis, CNVs with overlap-
ping 720 K CNVs also had a higher mean and median log2 ratio
than those that had no overlapping 720 K CNVs. An unpaired t-test
for groups of unequal size and variance was performed on the dif-
fering groups of log2 ratio means and found that the difference in
log2 ratio means between the sets was statistically signiﬁcantly
Table 1
Computer-aided single log2 ratio threshold comparison of two different array resolution designs.
Type of CNV Total number of all CNVs Number of common CNVs Number of unique CNVs
>100 Kb 385 K CNVs with 720 K Overlap 211 107 104
>100 Kb 385 K CNVs without 720 K Overlap 72 32 40
>400 Kb 385 K CNVs with 720 K Overlap 43 24 19
>400 Kb 385 K CNVs without 720 K Overlap 2 2 0
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niﬁcant for the 100 Kb analysis (p = 0.275). Subdividing these CNVs
into deletions and duplications yielded statistically similar results
for the 100 Kb (data not shown). Statistical tests could not be per-
formed for duplications and deletions separately in the 400 Kb CNV
cutoff group because of small numbers of CNVs. These analyses
suggested that the single most appropriate threshold metric for
future ROC analysis was the log2 ratio value and that our overall
approach of using a higher resolution array to conﬁrm a lower
resolution array is appropriate. This latter conclusion is based on
the observation that CNVs with overlap (true positives) were rep-
resented by signiﬁcantly more probes than those CNVs without
overlap (false positives) (p = 0.0454 for the 400 Kb analysis and
p = 2.19  1010 for the 100 Kb analysis). Thus, a CNV called with
more probes had a higher probability of being conﬁrmed with
the other array. Based on this analysis we chose to only calibrate
the log2 ratio threshold in this demonstration, however, it is possi-
ble to calibrate any algorithm metric using CNV-ROC.3.3. Computer-aided probe-based simultaneous CNV comparison and
metric calibration
Our next goal was to use CNV-ROC to ﬁnd the optimal log2 ratio
that could be used to call CNVs and maximize both genome-wide
sensitivity and speciﬁcity. This optimal log2 ratio could be calculat-
ed from a ROC analysis, which plots the sensitivity vs. false positive
rate as the threshold of an experimental metric is varied (in this
case the log2 ratio threshold at which to call a CNV in the 385 K
array). CNV-ROC uses a per-probe approach to both compare one
microarray against the other as well as calibrate one speciﬁc metric
(log2 ratio value) to optimize sensitivity and speciﬁcity. Amongst
the advantages of a per-probe based approach is the drastic
increase in data points for ROC analysis compared to a per-CNV
approach, however, the vast majority of these data points are true
negatives. This creates an unbalanced classiﬁcation problem that
can lead to false positive rates and speciﬁcities that are of less val-
ue. Thus, in addition to plotting traditional ROC curves of sensi-
tivity vs. false positive rate CNV-ROC also creates and analyzes
precision vs. recall curves.
Whereas this analysis could be performed on a per-CNV basis,
as with the manual analysis, the number of CNVs would be the
same and still lacking in ability to calculate robust performance
metrics. In addition, per-CNV based comparison approaches suffer
from the problem of having to arbitrarily choose a percentage of
overlap to classify a CNV as ‘‘matching’’ one from another platform.
These considerations led us to investigate a novel per-probe
approach that compared probes in CNV calls from the 385 K array
to calls from the 720 K array and assigned the 385 K probes ‘‘truth-
values’’ based on CNVs at the corresponding locations in the 720 K
array. This approach drastically increases the number of data
points available for comparative analysis and does not rely on
assigning an arbitrary percent overlap to establish identity. The
Nexus Copy Number FASST2 algorithm was run with log2 ratio
thresholds varying between 0.20 and 0.70 in increments of 0.05
to create 11 sets of CNV calls for both the 385 K and 720 K arrays
(Fig. 1). We chose to report our results at a CNV size of 400 Kb,however, CNV-ROC is capable of performing this analysis at any
user deﬁned size threshold. Because of the higher probe density,
CNVs called in the 720 K array were allowed to conﬁrm CNVs from
the 385 K array as true positives. Smaller 720 K array CNVs
(<400 Kb) were not used to penalize the 385 K array (false nega-
tives), because we were only assessing the performance of the
385 K array at a resolution of >400 Kb. Only 720 K CNVs greater
than 400 Kb could be used to call a false negative. We also allowed
CNVs >400 Kb on the 720 K array to conﬁrm smaller CNVs on the
385 K array while also allowing CNVs <400 Kb on the 720 K array
to conﬁrm larger CNVs on the 385 K array. These latter two situa-
tions were only used to calculate true positives and not false posi-
tives. We made this decision to account for two situations: (1)
when a CNV on the 385 K array was called just below the 400 Kb
size threshold but the same CNV was called on the 720 K array at
just over 400 Kb or vice versa, and (2) when a large CNV
(>400 Kb) gets fragmented into several smaller CNVs (<400 Kb)
by the CNV detection algorithm and as such would not be consid-
ered in the comparison because of the size threshold. In CNV-ROC
we provide an option to analyze CMA data both with and without
this option. Probes from the 385 K array with poor coverage (no
720 K probes located within a buffer of 15 Kb) were discarded from
the analysis. In the ROC analysis, a single 720 K log2 threshold was
used as a gold standard while 385 K arrays for each log2 ratio
threshold value were analyzed against it. CNV-ROC re-runs the
analysis for every 720 K log2 ratio threshold value (Fig. 1). All
385 K probes and 720 K probes were labeled by CNV-ROC as either
a CNV (deletion or duplication) or normal (not a CNV) using the
log2 ratio threshold and the CNV calls made by the FASST2 algo-
rithm (although any CNV calling algorithm could be used with
CNV-ROC). For each log2 ratio threshold tested against the gold
standard, all 385 K probes for each sample were assigned a truth-
value by CNV-ROC. The truth-value for each 385 K probe was
assigned as a true-positive or true-negative if one of the 720 K
array probes in its buffer range (15 Kb) had the same outcome
(gain, loss, normal/no CNV), otherwise the 385 K probe was labeled
as a false-positive or false-negative. CNV-ROC is capable of accu-
rately computing this information, given a paired set of microarray
data, in a few hours on a typical desktop workstation (Supplemen-
tal Protocol).
CNV-ROC produced a separate ROC curve for every 720 K gold
standard using a different log2 ratio threshold (Fig. 1). From the
ROC curves an optimal value for the log2 ratio threshold, or ‘‘sweet
spot’’, is determined by CNV-ROC by ﬁnding the closest point on
the curve to the ROC coordinate (0, 1) (Fig. 2 and Supplemental
Table 2). The optimal log2 ratio thresholds for the 385 K array fell
between 0.30 and 0.50 across all 720 K array log2 ratio threshold
conditions. Optimal log2 ratio thresholds for deletions and duplica-
tions were similar but not exactly the same (Table 2). Whereas this
analysis was capable of elucidating the optimal log2 ratio value to
use to maximize both sensitivity and speciﬁcity, the values
obtained for speciﬁcity were clearly biased toward the very large
number of true negative probes (non-CNV probes) present in the
array comparisons. This resulted in speciﬁcities that routinely
exceeded 99.999% across most 385 K log2 ratios thresholds tested.
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Fig. 1. Demonstration of a probe based ROC analysis performed using arrays of different resolution.
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Fig. 2. The top left image is a demonstration of how the optimal point is determined based on a normalized graph. Each point is labeled with the log2 ratio that was used to
call CNVs compared from the 385 K array to the CNVs called in the 720 K array with a 0.40 log2 ratio. The dotted vertical line represents the normalized maximum FPR and the
dotted horizontal line represents the normalized maximum sensitivity. The dashed diagonal line in the top left corner represents the shortest distance to the normalized
optimal point. A larger graph of the ‘‘knee’’ is also shown. The top right graph and bottom two graphs are ROC curves for 385 K CNVs greater than 400 Kb that use the 720 K
0.40 log2 threshold as a gold standard. The top right graph represents an analysis including all CNV types, the bottom left graph represents an analysis for just CNV
duplications, and the bottom right graph represents an analysis for just CNV deletions. All analyses are performed on a per-probe basis and have had their FPR normalized
using the average number of probes found in 385 K CNVs >400 Kb. The solid lines represent the analyses performed using all probes and the dotted lines represent the
analyses that exclude probes from common CNV regions.
Table 2
Optimal log2 ratio threshold determined for the 385 K array at every 720 K array log2
ratio threshold value using CNV-ROC.
720 K gold standard log2 ratio All CNV types Deletions Duplications
0.20 0.30 0.30 0.25
0.25 0.30 0.30 0.25
0.30 0.30 0.35 0.30
0.35 0.35 0.40 0.30
0.40 0.35 0.40 0.35
0.45 0.40 0.45 0.35
0.50 0.50 0.50 0.40
0.55 0.50 0.50 0.45
0.60 0.50 0.50 0.50
0.65 0.50 0.50 0.65
0.70 0.50 0.50 0.65
The optimal log2 ratio was determined for deletions, duplications, and a combina-
tion of both deletions and duplications. Overall, larger log2 ratio threshold are more
appropriate for duplications than for deletions. The larger range for duplications is
due to smaller numbers of CNV duplications.
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those values against one another similar to the more traditional
ROC analysis (Supplemental Fig. 2). Precision is calculated using
only true and false positives, is equivalent to the positive predictive
value, and is a more meaningful performance metric than speciﬁci-
ty or false positive rate using a per-probe approach. An alternative
transformation attempted was to normalize the number of TN
probes by dividing the total number of true negatives by theaverage number of probes present in CNVs >400 Kb. This seemed
appropriate given that a requirement for any true or false positive
probe was inclusion within a CNV that was >400 Kb. This transfor-
mation effectively reduced the number of true negative probes into
‘‘chunks’’ of true negative values equivalent to actual CNV-sized
segments. This option is also available in CNV-ROC if desired by
the user.
Once performance metrics were calculated, we determined the
most appropriate log2 ratio threshold for the 385 K array platform
by maximizing the trade-off between genome-wide sensitivity and
FPR as well as precision and recall. In performing this analysis we
looked at all CNVs taken together as well as only those CNVs that
would be presumed to have clinical signiﬁcance in constitution-
al/congenital genetic disorders. If we include all CNVs in our analy-
sis of the 385 K array we are unable to reach sensitivity and FPR
thresholds of the magnitude mentioned in the ACMG recommen-
dation manuscript. However, when we include only those probes
from CNVs that are considered clinically signiﬁcant, we deter-
mined that the best log2 ratio threshold to call duplications is
0.35, which produces a sensitivity of 99.4% with a lower limit of
the 95% conﬁdence interval of 98.2%, a speciﬁcity of 99.9% with a
lower limit of the 95% conﬁdence interval of 99.9%, and a precision
of 99.6% with a lower limit of the 95% conﬁdence interval of 98.5%.
Furthermore, we determined that the best log2 ratio threshold to
call deletions is 0.40, which produces a sensitivity of 99.7% with
a lower limit of the 95% conﬁdence interval of 99.1%, a speciﬁcity
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and a precision of 99.5% with a lower limit of the 95% conﬁdence
interval of 98.9%. If we used just one log2 ratio threshold to call
both duplications and deletions, the optimal log2 ratio threshold
was found to be 0.35 with a sensitivity, speciﬁcity, and precision
of 99.3% (lower 95% of 98.7%), 99.9% (lower 95% of 99.9%), and
99.5% (lower 95% of 99.0%). These log2 ratio threshold values were
the same whether we used the sensitivity vs. FPR plots or the pre-
cision vs. recall plots. Furthermore, these values are very similar to
those obtained by manual analysis, however, have much smaller
95% conﬁdence intervals.
Given that NimbleGen microarrays are no longer in production,
and in an effort to show that this methodology is robust, we also
tested whether a higher resolution Affymetrix microarray could
be used in a comparison with a lower resolution NimbleGen array.
With 20 new samples we used CNV-ROC with the Affymetrix
CytoScan HD microarray which has 1.9 million copy number
and 750,000 single nucleotide polymorphism (SNP) probes and
the NimbleGen 720 K array. We used the FASST2 algorithm to call
CNVs on the NimbleGen array and the SNP-FASST2 algorithm on
the Affymetrix CEL ﬁles to call CNVs on the CytoScan HD array
(Supplemental Materials). As both arrays were much higher
resolution we decreased our CNV size threshold to 100 Kb. The buf-
fer region size was changed from 15 Kb to 6 Kb based on the
resolution of the 720 K array. Lastly, based on the results from
the NimbleGen only comparison we choose to only test log2 ratio
values between 0.20 and 0.50. The results were similar, although
noticeably lower for duplications, and showed that at a size resolu-
tion of 100 Kb, when only clinically signiﬁcant CNVs were consid-
ered, a sensitivity, speciﬁcity, and precision of 85.8% (lower 95% of
84.9%), 99.9% (lower 95% of 99.9%), and 97.7% (lower 95% of 97.2%)
could be obtained for duplications with a log2 ratio threshold of
0.40, and 99.0% (lower 95% of 98.3%), 99.9% (lower 95% of 99.9%),
and 93.7% (lower 95% of 92.4%) for deletions with a log2 ratio of
0.40. (Supplemental Table 6 and Supplemental Fig. 3).4. Discussion
We have shown that clinical laboratories with access to two dif-
ferent resolution chromosomal microarray designs can perform a
cost-effective comparative analysis to calibrate speciﬁc algorithmic
metrics and establish the performance characteristics of their par-
ticular platform in their laboratory setting. This analysis is run with
a command line utility created in Perl, CNV-ROC, designed to run
on a desktop PC, typically taking only a few hours to run, but pos-
sibly upwards of one day depending on the sizes of arrays being
used and the log2 threshold ranges used in analyses. Whereas we
chose to perform this comparison on NimbleGen whole-genome
tiled CGH arrays and Affymetrix CytoScan HD arrays, the method-
ology used is robust and should be applicable to other oligonu-
cleotide-based designs. In fact, there is no design issue that
would preclude the use of CNV-ROC to compare CNV calls from
sequencing data as well as from chromosomal microarrays.
Several technical problems are present when trying to calculate
performance metrics for a CMA platform. The results from a CMA
platform need to be conﬁrmed with a separate test and ideally at
a resolution at which CMA provides its greatest utility. Readily
available technologies that could be used to conﬁrm the results
from CMA include FISH, quantitative PCR (qPCR), and multiplex
ligation-dependent probe ampliﬁcation (MLPA). The shortcoming
of these approaches is that none of them is a genome wide screen.
Comparison of microarray CNV ﬁndings with these technologies
provides for identiﬁcation of true and false positives but is gener-
ally lacking in true and false negatives. Without the later values,
sensitivity and speciﬁcity cannot strictly be calculated and anycomparison would be intrinsically biased toward overestimates
of these performance metrics [10]. These values could be calculat-
ed, for a limited, speciﬁc set of genetic loci but this is not an eco-
nomical way to assess the genome-wide coverage of CMA.
Conventional chromosome analysis (karyotyping) interrogates
the entire genome, however, the resolution of chromosome analy-
sis is such that only lesions of >5–10 Mb can be consistently and
reliably conﬁrmed. Our method described here allows for calcula-
tion of true and false positives (as is done in most FISH, qPCR, or
MLPA comparisons), as well as true and false negatives across
the entire genome. Previous publications have used these locus-
speciﬁc technologies to conﬁrm CMA ﬁndings [11–13]. Whereas
each of these publications illustrates the importance of CMA
results conﬁrmation none provide a demonstrable method for
the calculation of true and false negative values from CMA data.
Despite the high-throughput nature of our method, and the
ability to calculate true and false negatives, it is not without limita-
tions. The gold standard we used for our comparison is another
CMA design. Our analysis of probe numbers in true and false posi-
tive CNVs suggests that this comparison is valid, yet does not
address what is the most appropriate log2 ratio value to use with
the higher resolution array. To compensate for this, we tested the
lower resolution arrays against the higher resolution arrays at var-
ious log2 ratio thresholds and calculated the most appropriate log2
ratio threshold to use for the lower resolution array at every higher
resolution array log2 ratio threshold. This provided us with a range
for the optimum log2 ratio threshold for the lower resolution array
design. This range for the 385 K array, which was different for
duplications and deletions (duplication range: 0.25–0.65, deletion
range: 0.30–0.50), allowed us to determine what the optimal log2
ratio threshold should be when using the 385 K array design to
achieve a certain sensitivity and speciﬁcity for simultaneous test-
ing for both deletions and duplications. Our data also show that
comparing two arrays of markedly different designs and chemistry
results in lower performance metric values. This was especially
true for sensitivity and duplications. Whereas the use of CNV-
ROC for calibration of algorithmic metrics in such settings works
as anticipated, ﬁner tuning of CNV-ROC metrics, such as buffer
region size and common CNV regions, as well as CNV calling para-
meters, such as minimum number of probes to call a CNV, is likely
needed to optimize such comparisons.
We initially thought that the false positive rate might be better
represented if the ROC analysis were performed for regions instead
of probes, however conducting region-based analyses proved chal-
lenging due to the incomplete classiﬁcation of non-CNV regions
with a truth-value. The arrays could be quantiﬁed into CNV regions
and non-CNV regions, but precise classiﬁcation of the regions as
different algorithmic metrics were altered proved difﬁcult. We
found that a probe-based analysis provided roughly uniform spac-
ing and coverage between differing array types making it easier to
assign truth-values to the probes. Comparison of two CNVs to one
another to determine if they are the same is a difﬁcult task. Break-
point uniformity is often very poor and differences in probe cover-
age between different arrays leads to loss of CNVs and reducing the
power of the analysis [14]. The use of a per-probe approach over-
came these limitations. Fragmentation of CNV calls, however, still
proved a problem when performing the comparative analysis at
speciﬁc CNV size thresholds. To compensate for this phenomenon,
as well as address subtle differences in breakpoints, we added an
option to CNV-ROC that allows CNVs smaller than the speciﬁed
size threshold to conﬁrm comparison CNVs in the other array that
are above the size threshold. Furthermore, given the nature of the
per-probe analysis, larger CNVs will contribute more to the perfor-
mance metrics calculations than smaller ones given the larger
number of probes contained within larger CNVs. This behavior is
not unintended as it reduces performance metrics more severely
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false positives or false negatives).
Calculation of performance metrics with CNV-ROC is capable of
using common, polymorphic CNVs. By including both unique and
common CNVs we greatly increase the total number of CNV-relat-
ed probes available for evaluation. An additional advantage of this
approach is that following this type of comparison the microarray
platform under consideration has been tested against a wide range
of polymorphic CNVs in addition to those that are currently sought
after in constitutional genetic conditions. Whereas polymorphic
CNVs are generally not considered signiﬁcant in terms of develop-
mental disorders, they have been shown in several publications to
convey quantiﬁable risk of common diseases [15,16]. For the com-
parison between the two NimbleGen arrays, both of which are
comparative genomic hybridization arrays, we observed that the
probe-based sensitivity of our array platform is lower when con-
sidering all CNVs than when considering just those that are unique
and likely clinically signiﬁcant. We believe the explanation for this
is that most common CNVs are part of segmental duplications and
are very polymorphic in the general population. This makes the
choice of reference DNA very important. We chose to use reference
DNA that is a combination of genomic DNA from several indi-
viduals of the same sex. It is likely that within this mix of indi-
viduals there are different genotypes at several segmental
duplication loci. This results in ‘‘blunted’’ log2 ratio values of
patient to reference signal at probes representing these loci. These
lower ratios are often right at the log2 ratio threshold and are occa-
sionally not detected on one or the other platform. Given that we
are dealing with higher and lower resolution platforms, it is more
common for these instances to be missed on the lower resolution
platform and be classiﬁed as false negatives, thus lowering the sen-
sitivity. All the false negatives we identiﬁed were within highly
polymorphic regions of the genome and considered to be clinically
benign.
Here we describe an approach and a command line utility, CNV-
ROC, which allows clinical laboratories to calibrate various algo-
rithmic metrics as well as calculate probe-based performance
metrics.
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